• About
        • About Us

          Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of plant defensin peptides for applications as human therapeutics.

        • About Hexima

        • About Us
        • Leadership
        • News & Presentations
        • Contact Us

        • Contact Us
  • Technology
        • Technology

          Antifungal plant defensin technology platform.

        • Our Technology

        • Antifungal Plant Defensins
        •  

        • Literature
  • Products
        • Products

          Safe and effective application of the plant defensin technology to the treatment of human fungal disease.

        • Products

        • Pezadeftide
        • Medical Applications

        • Onychomycosis
        • KOL Interviews
  • News & Presentations
  • Investors
        • Investors

          Share price, ASX announcements and investor resources.

        • Investor Resources

        • Investor Centre
        • Corporate Governance
        • ASX Announcements
        • Blank

        • Annual & Interim Reports
        • Investor Services
  • About
        • About Us

          Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of plant defensin peptides for applications as human therapeutics.

        • About Hexima

        • About Us
        • Leadership
        • News & Presentations
        • Contact Us

        • Contact Us
  • Technology
        • Technology

          Antifungal plant defensin technology platform.

        • Our Technology

        • Antifungal Plant Defensins
        •  

        • Literature
  • Products
        • Products

          Safe and effective application of the plant defensin technology to the treatment of human fungal disease.

        • Products

        • Pezadeftide
        • Medical Applications

        • Onychomycosis
        • KOL Interviews
  • News & Presentations
  • Investors
        • Investors

          Share price, ASX announcements and investor resources.

        • Investor Resources

        • Investor Centre
        • Corporate Governance
        • ASX Announcements
        • Blank

        • Annual & Interim Reports
        • Investor Services

Annual & Interim Reports

Current Reports

Annual Report

Download

Interim Report

Download

Previous Reports

Title

2022 Interim Financial Report

2021 Annual Financial Report

2021 Interim Financial Report

2020 Annual Financial Report

2020 Interim Financial Report

2019 Annual Financial Report

2019 Interim Financial Report

2018 Annual Financial Report

2018 Interim Financial Report

2017 Annual Financial Report

2017 Interim Financial Report

2016 Annual Financial Report

2016 Interim Financial Report

2015 Annual Financial Report

2015 Interim Financial Report

2014 Annual Financial Report

2014 Interim Financial Report

2013 Annual Financial Report

2013 Interim Financial Report

2012 Annual Financial Report

2012 Interim Financial Report

2011 Annual Financial Report

2011 Interim Financial Report

2010 Annual Financial Report

2010 Interim Financial Report

2009 Annual Financial Report

2009 Interim Financial Report

2008 Annual Financial Report

2008 Interim Financial Report

2007 Annual Financial Report

 

About Us

Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of plant defensin peptides for applications as human therapeutics.

  • Follow
  • Follow

Contact

Hexima Limited
Level 4, LIMS2
La Trobe University VIC 3086
Australia

Phone: +61 3 9479 1210

Stay up to date

For the latest shareholder information & investor news, subscribe to our email alerts.

Subscribe
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume you accept these cookies and agree to our privacy policy.OkPrivacy policy